Cargando…

Rapid increase of Plasmodium falciparum dhfr/dhps resistant haplotypes, after the adoption of sulphadoxine-pyrimethamine as first line treatment in 2002, in southern Mozambique

BACKGROUND: In late 2002, the health authorities of Mozambique implemented sulphadoxine-pyrimethamine (SP)/amodiaquine (AQ) as first-line treatment against uncomplicated falciparum malaria. In 2004, this has been altered to SP/artesunate in line with WHO recommendations of using Artemisinin Combinat...

Descripción completa

Detalles Bibliográficos
Autores principales: Enosse, Sonia, Magnussen, Pascal, Abacassamo, Fatima, Gómez-Olivé, Xavier, Rønn, Anita M, Thompson, Ricardo, Alifrangis, Michael
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2481262/
https://www.ncbi.nlm.nih.gov/pubmed/18590577
http://dx.doi.org/10.1186/1475-2875-7-115
_version_ 1782157972516896768
author Enosse, Sonia
Magnussen, Pascal
Abacassamo, Fatima
Gómez-Olivé, Xavier
Rønn, Anita M
Thompson, Ricardo
Alifrangis, Michael
author_facet Enosse, Sonia
Magnussen, Pascal
Abacassamo, Fatima
Gómez-Olivé, Xavier
Rønn, Anita M
Thompson, Ricardo
Alifrangis, Michael
author_sort Enosse, Sonia
collection PubMed
description BACKGROUND: In late 2002, the health authorities of Mozambique implemented sulphadoxine-pyrimethamine (SP)/amodiaquine (AQ) as first-line treatment against uncomplicated falciparum malaria. In 2004, this has been altered to SP/artesunate in line with WHO recommendations of using Artemisinin Combination Therapies (ACTs), despite the fact that all the neighbouring countries have abandoned SP-drug combinations due to high levels of SP drug resistance. In the study area, one year prior to the change to SP/AQ, SP alone was used to treat uncomplicated malaria cases. The study described here investigated the immediate impact of the change to SP on the frequency of SP and CQ resistance-related haplotypes in the Plasmodium falciparum genes Pfdhfr, Pfdhps and Pfcrt before and a year after the introduction of SP. METHODS: Samples were collected during two cross sectional surveys in early 2002 and 2003 involving 796 and 692 children one year or older and adults randomly selected living in Maciana, an area located in Manhiça district, Southern Mozambique. Out of these, 171 and 173 P. falciparum positive samples were randomly selected to measure the frequency of resistance- related haplotypes in Pfdhfr, Pfdhps and Pfcrt based on results obtained by nested PCR followed by sequence-specific oligonucleotide probe (SSOP)-ELISA. RESULTS: The frequency of the SP-resistance associated Pfdhps double mutant (SGEAA) haplotype increased significantly from 14% to 35% (P < 0.001), while the triple mutant Pfdhfr haplotype (CIRNI) remained high and only changed marginally from 46% to 53% (P = 0.405) after one year with SP as first-line treatment in the study area. Conversely, the combined Pfdhfr/Pfdhps quintuple mutant haplotype increased from 8% to 26% (P = 0.005). The frequency of the chloroquine resistance associated Pfcrt-CVIET haplotype was above 90% in both years. CONCLUSION: These retrospective findings add to the general concern on the lifespan of the combination of SP/artesunate in Mozambique. The high frequency of quintuple Pfdhfr/Pfdhps haplotypes found here as early as 2002 most likely cause ideal conditions for the development of artesunate tolerance in the P. falciparum populations and may even endanger the sensitivity to the second-line drug, Coartem(®).
format Text
id pubmed-2481262
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-24812622008-07-23 Rapid increase of Plasmodium falciparum dhfr/dhps resistant haplotypes, after the adoption of sulphadoxine-pyrimethamine as first line treatment in 2002, in southern Mozambique Enosse, Sonia Magnussen, Pascal Abacassamo, Fatima Gómez-Olivé, Xavier Rønn, Anita M Thompson, Ricardo Alifrangis, Michael Malar J Research BACKGROUND: In late 2002, the health authorities of Mozambique implemented sulphadoxine-pyrimethamine (SP)/amodiaquine (AQ) as first-line treatment against uncomplicated falciparum malaria. In 2004, this has been altered to SP/artesunate in line with WHO recommendations of using Artemisinin Combination Therapies (ACTs), despite the fact that all the neighbouring countries have abandoned SP-drug combinations due to high levels of SP drug resistance. In the study area, one year prior to the change to SP/AQ, SP alone was used to treat uncomplicated malaria cases. The study described here investigated the immediate impact of the change to SP on the frequency of SP and CQ resistance-related haplotypes in the Plasmodium falciparum genes Pfdhfr, Pfdhps and Pfcrt before and a year after the introduction of SP. METHODS: Samples were collected during two cross sectional surveys in early 2002 and 2003 involving 796 and 692 children one year or older and adults randomly selected living in Maciana, an area located in Manhiça district, Southern Mozambique. Out of these, 171 and 173 P. falciparum positive samples were randomly selected to measure the frequency of resistance- related haplotypes in Pfdhfr, Pfdhps and Pfcrt based on results obtained by nested PCR followed by sequence-specific oligonucleotide probe (SSOP)-ELISA. RESULTS: The frequency of the SP-resistance associated Pfdhps double mutant (SGEAA) haplotype increased significantly from 14% to 35% (P < 0.001), while the triple mutant Pfdhfr haplotype (CIRNI) remained high and only changed marginally from 46% to 53% (P = 0.405) after one year with SP as first-line treatment in the study area. Conversely, the combined Pfdhfr/Pfdhps quintuple mutant haplotype increased from 8% to 26% (P = 0.005). The frequency of the chloroquine resistance associated Pfcrt-CVIET haplotype was above 90% in both years. CONCLUSION: These retrospective findings add to the general concern on the lifespan of the combination of SP/artesunate in Mozambique. The high frequency of quintuple Pfdhfr/Pfdhps haplotypes found here as early as 2002 most likely cause ideal conditions for the development of artesunate tolerance in the P. falciparum populations and may even endanger the sensitivity to the second-line drug, Coartem(®). BioMed Central 2008-07-01 /pmc/articles/PMC2481262/ /pubmed/18590577 http://dx.doi.org/10.1186/1475-2875-7-115 Text en Copyright © 2008 Enosse et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Enosse, Sonia
Magnussen, Pascal
Abacassamo, Fatima
Gómez-Olivé, Xavier
Rønn, Anita M
Thompson, Ricardo
Alifrangis, Michael
Rapid increase of Plasmodium falciparum dhfr/dhps resistant haplotypes, after the adoption of sulphadoxine-pyrimethamine as first line treatment in 2002, in southern Mozambique
title Rapid increase of Plasmodium falciparum dhfr/dhps resistant haplotypes, after the adoption of sulphadoxine-pyrimethamine as first line treatment in 2002, in southern Mozambique
title_full Rapid increase of Plasmodium falciparum dhfr/dhps resistant haplotypes, after the adoption of sulphadoxine-pyrimethamine as first line treatment in 2002, in southern Mozambique
title_fullStr Rapid increase of Plasmodium falciparum dhfr/dhps resistant haplotypes, after the adoption of sulphadoxine-pyrimethamine as first line treatment in 2002, in southern Mozambique
title_full_unstemmed Rapid increase of Plasmodium falciparum dhfr/dhps resistant haplotypes, after the adoption of sulphadoxine-pyrimethamine as first line treatment in 2002, in southern Mozambique
title_short Rapid increase of Plasmodium falciparum dhfr/dhps resistant haplotypes, after the adoption of sulphadoxine-pyrimethamine as first line treatment in 2002, in southern Mozambique
title_sort rapid increase of plasmodium falciparum dhfr/dhps resistant haplotypes, after the adoption of sulphadoxine-pyrimethamine as first line treatment in 2002, in southern mozambique
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2481262/
https://www.ncbi.nlm.nih.gov/pubmed/18590577
http://dx.doi.org/10.1186/1475-2875-7-115
work_keys_str_mv AT enossesonia rapidincreaseofplasmodiumfalciparumdhfrdhpsresistanthaplotypesaftertheadoptionofsulphadoxinepyrimethamineasfirstlinetreatmentin2002insouthernmozambique
AT magnussenpascal rapidincreaseofplasmodiumfalciparumdhfrdhpsresistanthaplotypesaftertheadoptionofsulphadoxinepyrimethamineasfirstlinetreatmentin2002insouthernmozambique
AT abacassamofatima rapidincreaseofplasmodiumfalciparumdhfrdhpsresistanthaplotypesaftertheadoptionofsulphadoxinepyrimethamineasfirstlinetreatmentin2002insouthernmozambique
AT gomezolivexavier rapidincreaseofplasmodiumfalciparumdhfrdhpsresistanthaplotypesaftertheadoptionofsulphadoxinepyrimethamineasfirstlinetreatmentin2002insouthernmozambique
AT rønnanitam rapidincreaseofplasmodiumfalciparumdhfrdhpsresistanthaplotypesaftertheadoptionofsulphadoxinepyrimethamineasfirstlinetreatmentin2002insouthernmozambique
AT thompsonricardo rapidincreaseofplasmodiumfalciparumdhfrdhpsresistanthaplotypesaftertheadoptionofsulphadoxinepyrimethamineasfirstlinetreatmentin2002insouthernmozambique
AT alifrangismichael rapidincreaseofplasmodiumfalciparumdhfrdhpsresistanthaplotypesaftertheadoptionofsulphadoxinepyrimethamineasfirstlinetreatmentin2002insouthernmozambique